<DOC>
	<DOCNO>NCT02463591</DOCNO>
	<brief_summary>The purpose study investigate whether Prothrombin Complex Concentrate ( PCC ) effective reverse anticoagulant effect Dabigatran , assess two modified skin-bleeding test .</brief_summary>
	<brief_title>Reversal Dabigatran With Prothrombin Complex Concentrate</brief_title>
	<detailed_description>There currently treatment widely available immediate reversal Dabigatran anticoagulant effect , e.g . case major bleed emergency surgery invasive procedure indicate . Treatment prothrombin complex concentrate ( PCC ) seem effective reduce blood loss animal model , previous study human fail show effect blood coagulation parameter . Recently , two novel method skin blood loss , one call `` shed blood '' another `` wash blood '' able measure effect anticoagulation , either inhibition fibrin formation wound site measure Fibrinopeptide A ( FPA ) elevate blood loss , respectively , oral administration Dabigatran healthy volunteer . The investigator hypothesise shed/washed blood method able measure Dabigatran reversal follow administration PCC ( Beriplex ) . The study perform randomise double blind cross-over study 12 healthy human male subject enrol . Subjects take Dabigatran 300 mg b.i.d . day -2 , -1 0 . After fifth dose ( day 0 ) , subject randomise receive Beriplex ( 50 IU/kg ) similar volume saline single bolus dose i.v . 20 minute . After 10 day minimum wash-out period procedure repeat , alternative treatment ( Saline Beriplex ) administer . The Shed / Washed Blood measurement perform different time point start oral anticoagulant administration Beriplex/Saline . In addition Shed / Washed blood test , several ex vivo standard coagulation test perform . These include : activate partial thromboplastin time ( aPTT ) , prothrombin time ( PT ) , dilute thrombin time ( DTT/Hemoclot ) , Dabigatran plasma level ( use liquid chromatography-tandem mass spectrometry ( LC-MS/MS ) ) , endogenous thrombin generation ( ETG ) pre post factor II , VII , IX X .</detailed_description>
	<mesh_term>Dabigatran</mesh_term>
	<mesh_term>Thrombin</mesh_term>
	<criteria>Healthy male Age 18 50 year Weight &lt; 100 kg Signed informed consent eGFR â‰¥ 80ml/min*1.73m2 History allergic reaction blood product Current participation investigational drug study within past 30 day Increased bleeding tendency history thrombosis Anticoagulant medication , platelet aggregation inhibitor NSAIDs Use medication 14 day start dabigatran intake</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Direct Thrombin Inhibitor</keyword>
	<keyword>Prothrombin Complex Concentrate</keyword>
	<keyword>Dabigatran Etexilate</keyword>
	<keyword>Beriplex</keyword>
	<keyword>Shed Blood</keyword>
	<keyword>Washed Blood</keyword>
	<keyword>Fibrinopeptide A</keyword>
</DOC>